Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Vibrio cholerae O1 lipopolysaccharide antigen (O1 LPS antigen) is a surface carbohydrate structure and the primary serogroup-defining antigen of *V. cholerae* O1, the strain responsible for most cholera pandemics. The O1 LPS antigen comprises a homopolymer of perosamine residues as the O-specific polysaccharide (OSP) attached to the core oligosaccharide and lipid A of the bacterial outer membrane[2][4][5]. It determines O1 serogroup and serotype (Ogawa, Inaba, Hikojima) specificity, crucial for virulence, colonization, and immune recognition[4][7]. The O1 antigen is the main target for protective antibody responses after infection and vaccination, providing the rationale for current vaccine strategies[5][6]. It is also targeted by bacteriophages and subject to phase variation and serotype switching, allowing immune evasion and adaptation within hosts or epidemics[1][7]. Although not a classical drug target for small molecules, it is under active investigation for vaccine development and as a biomarker for immune protection or exposure[6]. Key features: - **Structural class:** O-specific polysaccharide component of LPS, attached to outer membrane lipid A[2][3][4]. - **Virulence:** Essential for host colonization, infectiousness, and protection against bacteriophage predation[1][4]. - **Vaccine target:** Main antigen in current and in-development cholera vaccines[5][6]. - **Serotype specificity:** Variation in O1 antigen determines serotype (Ogawa, Inaba, Hikojima), based on methylation status of terminal perosamine[4][5][7]. - **Immunogenicity:** Induces robust IgG, IgM, and IgA responses, closely correlating with vibriocidal antibody titers, serving as correlates of protection[6]. - **Antigenic variation:** Phase variable genes (e.g., manA, wbeL, rfbT) control biosynthesis and enable intra-strain O1 expression diversity, affecting vaccine efficacy and immune escape potential[1][4][7].
Antibody neutralization; Bacteriophage lysis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vibrio cholerae O1 lipopolysaccharide antigen.